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Summary We have treated 40 patients was relapsed or resistant lymphoma with the combination of
Etoposide, Prednisolone, Ifosfamide and Cisplatin (EPIC). Complete response was obtained in 11 patients
(28%) with an overall response of 58%. The presence of bulky disease (P<0.005), elevated LDH serum levels
(P<0.005), response to prior chemotherapy (P<0.01) and B symptoms (P<0.05) were significantly
associated with response. However on multivariate analysis only the presence of bulky disease and of B
symptoms were independent adverse factors for response and for survival. The regimen was well tolerated with
myelosuppression being the most common toxicity. Leucopenia < 1,000jil-I and thrombocytopenia
< 25,000A1l
` developed in 27% and 4% of cycles respectively. There were no treatment related deaths. The
EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of
recurrent lymphoma, but is associated with lower treatment related morbidity and mortality.
Most patients with aggressive' non-Hodgkin's lymphoma
(NHL) and Hodgkin's disease (HD) relapsing or resistant to
front line chemotherapy have a poor prognosis (De Vita et
al., 1989; Cabanillas et al., 1990; Longo, 1990). Although
good initial responses have been reported with several sal-
vage regimens, toxicity is significant and long term disease
free survival low (Cabanillas et al., 1982; Cabanillas et al.,
1987; Velasquez et al., 1988; Hagemeister et al., 1987; San-
toro et al., 1986). There is therefore a requirement for more
effective low toxicity regimens. In an attempt to meet this
need we devised a new salvage chemotherapy combination
which includes etoposide, prednisolone, ifosfamide and cis-
platin (EPIC). These drugs have different mechanisms of
action (Achterrath et al., 1982; Colvin, 1982; Zwelling &
Kohn, 1979; Plooy et al., 1984). The biological rationale for
this schedule is derived from the single agent activity of these
drugs in lymphoma, (Cavalli et al., 1981; Rodriguez et al.,
1978; Taylor et al., 1982) the in vitro and in vivo data
suggesting synergy between them (Achterrath et al., 1982;
Schabel et al., 1979; Dewinko et al., 1976; Frei et al., 1988;
Goldin, 1982; Durand & Goldie, 1987) and the lack of cross
resistance between cisplatin and drugs used in first line com-
binations (Schabel et al., 1979). Also there is evidence of
incomplete cross resistance between ifosfamide and cyclo-
phosphamide (Hilgard et al., 1983).
Clinical benefits have been reported with the use of these
drugs in different schedules (Judson & Wiltshaw, 1985;
Scheulen et al., 1983). Furthermore, investigators at the MD
Anderson Hospital have demonstrated that in relapsed and
resistant lymphoma the substitution of etoposide for vincris-
tine in a combination which also included ifosfamide and
methotrexate increased the CR rate from 17% to 37%
(Cabanillas et al., 1982; Cabanillas et al., 1980). Similarly the
addition of 100 mg m2 cisplatin to the ESA schedule
(etoposide, Methylprednisolone, cytarabine) raised the overall
response rate from 38% to 69% (Cabanillas et al., 1988).
Therefore the clinical evidence supports the experimental
data indicating activity and at least an additive effect of these
drugs in relapsed and resistant lymphoma.
In this study we describe our experience with the EPIC
protocol in the management of these patients.
Patients and methods
Patient selection
Thirty-two patients with NHL and 10 with HD were enrolled
into this trial between November 1989 and March 1991.
Eligibility criteria included the following: (1) biopsy proven
relapsing or resistant NHL or HD; (2) measurable disease;
(3) informed consent; (4) EDTA >60 ml min-'. Response to
prior chemotherapy was defined according to WHO criteria
(Miller et al., 1981). Patients were then classified as follows:
- Relapse from prior remission (CR or PR).
- Primary resistant disease; failure to achieve a remission
(PR or CR) with any chemotherapy used in the past.
The purpose of this classification was to group patients in
terms of the chemosensitivity prior to implementing EPIC
chemotherapy.
All but two patients with NHL had been exposed to
alkylating agents and anthracyclines in previous combina-
tions. The two exceptions were patients with follicular NHL
treated with CVP and one of these had also received high
dose therapy plus autologous bone marrow transplantation
(ABMT). The patients with HD had all been treated with
both a MOPP type and an anthracycline containing com-
bination. In addition, seven had been treated with extended
field radiotherapy and three with high dose chemotherapy
and bone marrow transplant in the past.
Bulky disease was considered to be present if any mass
measured>5cm in diameter on CT evaluation or clinical
examination.
Patient's characteristics are shown in Table I. Staging was
conducted prior to the first cycle of chemotherapy and
included clinical examination, full blood count, usual serum
chemistries, chest radiograph and computer tomography
(CT) scan ofchest, abdomen and pelvis. An EDTA clearance
test was performed before every other cycle unless clinically
indicated. Restaging with the appropriate imaging technique
was performed every two courses. MRI and high dose Gal-
lium scans were performed at the completion of therapy if a
residual mass was shown on CT.
Chemotherapy
The dose schedule of the EPIC regimen is as follows:
Etoposide 100mgm2 intravenous in 500ml N-saline over
1 h on Days 1-4; Ifosfamide 1 g m2 by bolus intavenous on
Days 1-5 with hydration and Mesna; Prednisolone 100 mg
daily orally on Days 1-5; cisplatin 60 mg m-2 by short
intravenous infusion with hydration and anti-emetics on Day
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Table I Patient characteristics
No. %
All patients
Age Mean (range)
Gender
Male
Female
Histology
Intermediate grade NHL
Diffuse immunoblastic (3 transformed)
Diffuse large cell (2 transformed)
Diffuse mixed (1 transformed)
Follicular large cell
Peripheral T cell
Low grade NHL
Follicular small cleaved
Follicular mixed
Hodgkin's disease
Nodular sclerosis
Mixed cellularity
Number of previous treatments
One
>,2
Response to prior therapy
CR
PR
Primary resistant disease
Interval in remission (19 patients)
< 3 months
3-6 months
6-12 months
> 12 months
Stage
IIA
IIB
IIIA
IIIB
IVA
IVB
BM involvement
Yes
No
Not investigated
Extranodal involvement
None
One site
> 2 sites
Bulky disease
Present
Absent
B symptoms
Present
Absent
LDH serum levels (25 patients)
< 240
>240 (elevated)
40 100
50 (19-68)
23
17
29
14
7
5
2
1
2
9
7
2
17
23
9
10
21
9
6
2
2
3
2
1
4
11
19
12
27
1
10
13
17
19
21
25
15
14
11
58
42
parametric test as indicated, and their independent effect was
tested using the logistic regression model (Lehmann, 1959).
Results
Response rates
Forty patients were evaluable for response. CR was obtained
73 in 11 patients (28%) and PR in 12 (30%), with an overall
response rate of 58%. Two patients were excluded from the
final analysis of response - one was found to have a second
neoplasm instead of a relapsed NHL. The other, a patient
with HD who had achieved CR, was excluded because in
5 retrospect we could not exclude an effect of the prior
chemotherapy in the response. However these two patients
were included in the toxicity analysis. The response rates
22 associated with several prognostic factors are shown in Table
II. Patients relapsing from a CR achieved a response of 89%,
while only three patients (27%) with primary resistant disease
42 responsed (P<0.01). The overall response rate for NHL
58 16/31 (48%) was not significantly different from that of HD 7/9 (78%). Stage, bone marrow involvement or number of
22 extranodal sites affected did not correlate with the quality of
25 response and response rate. The presence of B symptoms
53 (P<0.05), bulky disease (P<0.005) and elevated LDH
(P<0.005) were poor prognostic features. However on multi-
47 variate analysis only bulky disease and the presence of B
32 symptoms were independent predictors of response and sur-
11 vival. Patients with absence ofbulky disease and B symptoms 11 (nine patients) had a response rate of 100% compared with
8 56% of those with only one or them and 8% of those with
5 both bulky disease and B symptoms.
2 Patients with transformed NHL did worse than other
10 intermediate grade NHL, but the difference was not
28 significant.
47 Seven patients with HD (78%) had a PR. There were no
CRs. Five of these patients were subsequently treated with
30 high dose therapy and marrow transplantation. The other
3 two had already been treated with bone marrow transplanta-
tion before EPIC.
25
33 Time to treatmentfailure andsurvival
48
52
62
38
56
44
10 provided EDTA clearance )60 ml min-. Treatment was
given as an in-patient and was repeated every 3 weeks.
Chemotherapy was delayed if white cell count <2,000 ul
or platelets <100,0001l-' on day one. Cimetidine, co-
trimoxazole and antifungal prophylaxis with oral nystatin
and amphotericin were given throughout the treatment. The
response to EPIC and toxicity were determined using the
WHO criteria (Miller et al., 1981).
Statistical analysis
Time to treatment failure (TTF; time to relapse, progression
or death) and duration of survival were calculated from the
beginning of treatment. Survival curves were estimated by the
method of Kaplan and Meier (Peto et al., 1977). The Log
rank test was utilised to compared differences in survival and
TTF (Peto et al., 1977). The proportional hazards model was
used to determine the independence of factors for survival
(Cox, 1972). Prognostic factors for response were compared
using chi-square, Fisher exact or Mann Whitney non
TTF and survival are shown in Figures 1, 2 and 3. Median
TTF is 18 months for CR and 6 months for PR (P<0.005).
Seven (30%) of the patients who responded remain free of
disease, with a median follow up of 12 (4-15) months. The
median survival for the whole group of patients is 9 months.
There is no difference in survival for NHL vs HD. The TTF
for patients with NHL is marginally better than that for
those with HD (P= 0.07). Median survival for CR, PR and
non responders is 21, 12 and 6 months respectively
(P<0.005). Fourteen patients remain alive, with a median
follow up of 13 (4-21) months. One died from a second
neoplasm soon after achieving PR.
Toxicity and chemotherapy
The EPIC regimen was generally well tolerated. A total of
150 courses of treatment were given to 42 patients, with a
median 3 (1-8) cycles. The most frequent significant side-
effect was myelosuppression (see Table III). Forty episodes of
WHO grade 4 leucopenia (WBC 10001tl-') were found in
23 patients. Delay of therapy usually due to myelosuppres-
sion or infection, occurred in 20 patients with a median delay
of 2 weeks per patient. Twelve episodes of fever with neut-
ropenia (8%) were recorded, including three that were severe
(WHO grade 3). Two non-disseminated Herpes-Zoster infec-
tions were also found. Alopecia was almost universal.
Nausea and vomiting were usually moderate, only one
patient developing WHO grade 3 toxicity. Mucositis was rare
and haemorrhagic cystitis was not found in our patients.
Two patients had reversible impairment of renal function and
cisplatin was omitted in one and two courses respectively.
The dose of etoposide was reduced by 25% in two patientsLOW TOXICITY REGIMEN FOR RELAPSING LYMPHOMA 601
Table II Response to EPIC regimen
Response
CR CR + PR P value
Patient characteristics No. % No. % (overall response)
All patients (40) 11 28 23 58
Histology
Intermediate grade NHL 11 38 14 48 NS
Low grade NHL - - 2 100
Hodgkin's disease - - 7 78
Response to prior chemotherapy
CR 5 56 8 89 P<0.05
PR 4 40 6 60
Primary resistant disease 2 10 9 43
B symptoms
Present 5 20 11 44 P<0.05
Absent 6 40 12 80
Bulky disease
Present 4 21 4 21 P<0.005
Absent 7 33 19 90
LDH
<240 5 36 11 79 P<0.005
>240 (elevated) 2 29 2 29
Extranodal site
None 3 30 6 60 NS
One 4 31 8 62
Two or more 4 24 9 53
NS = non significant.
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Figure 1 Time to treatment failure for patients who achieved
either CR ( ) or PR (---).
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Figure 3 Time to treatment failure for Hodgkin's disease
( ~) and non-Hodgkin's lymphoma (---).
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Figure 2 Kaplan and Meier survival curve for patients achieving
CR ( ), PR (---) and non-responders ( --).
Table III Toxicity
Toxicity No. of patients %
All patients 42
Myelotoxicity (WHO grade 4)
WBC < 1,000 - l 23 55
Platelets <25,000jl1-' 3 7
Neutropenic fever 10 24
Grade 3 3
Grade 2 7
Other infections
Herpes zoster 2 5
Hickman line infection 1 2
Nausea and vomiting 20 48
Grade 3 1
Grade 2 7
Grade 1 12
Mucositis 2 5
Peripheral neuropathy 2 5
Renal toxicity (reversible) 2 5
Ifosfamide encephalopathy (reversible) 1 2
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following a septic episode. Ifosfamide was reduced by 50% in
a patient with tremor. Two other patients had a 20% reduc-
tion of ifosfamide, one because of renal impairment and the
other following an episode of neutropenic fever. In one
patient a dose of cisplatin was omitted because of neut-
ropenia.
In five patients treatment was discontinued after one
course of chemotherapy. One had had high dose chemo-
therapy with ABMT and developed prolonged thrombo-
cytopenia. The other four had progressive disease.
Discussion
Several therapeutic alternatives have been developed for
patients with NHL who had failed first line doxorubicin and
cyclophosphamide containing regimens. These include the use
of drug combinations, theoretically non cross resistant with
first line regimens, the reversal of multidrug resistance and
the use of high dose chemotherapy with ABMT.
The role for intensive chemotherapy with ABMT in
relapsed NHL is undecided. However Philip et al. have
reported an actuarial 3 year disease-free survival after ABMT
of 0% and 14% for NHL patient with refractory and resis-
tant relapsed disease respectively (Philip et al., 1987).
Moreover, long term disease free survival is around 20% in
non selected groups of patient, (Takvorian et al., 1987;
Appelbaum et al., 1987; Phillips et al., 1990) results not much
better than those achieved with conventional salvage therapy
alone. This indicates that in relapsed NHL, intensive chemo-
therapy with ABMT only has a place in patients who have
sensitive disease and low tumour burden after salvage
therapy (Philip et al., 1987; Takvorian et al., 1987). In
patients achieving CR with salvage chemotherapy the advan-
tage of intensive chemotherapy is not clear and the results of
ongoing trials, such as the Parma study, are eagerly awaited
(Philip et al., 1991). Patients achieving only a PR with a
second line chemotherapy have a very poor prognosis, and
should probably be offered intensive therapy with ABMT in
an attempt to achieve long term remissions.
Another approach is to overcome drug resistance by
infusional therapy with doxorubicin and vincristine or by the
addition of a P-170 glycoprotein blocking agent to those
combinations (Chabner & Wilson, 1991). Miller et al. have
reported a response rate of 72% in 18 NHL and HD patients
using a prolonged continuous infusion of verapamil plus
doxorubicin and vincristine together with cyclophosphamide
and dexamethasone (Miller et al., 1991).
The EPIC regimen is an attempt to develop a new
chemotherapy combination for relapsed and resistant lym-
phoma non cross resistant with first line regimens. The
results of several such combinations have been published (see
Table IV). Of particular interest are the series of trials by the
MD Anderson Hospital Group. When comparing these
regimens in terms of response it is clearly crucial to be
mindful of the difference in case selection (Press et al., 1991).
Patients with primary resistant lymphomas and resistant
relapse do particularly badly (Cabanillas et al., 1982;
Cabanillas et al., 1987; Philip et al., 1987; Takvorian et al.,
1987; Appelbaum et al., 1987; Phillips et al., 1990). Several
othe prognostic features for relapsed lymphoma have been
reported. These include the duration of response to first line
chemotherapy (Cabanillas et al., 1982) elevated serum LDH,
(Cabanillas et al., 1987; Velasquez et al., 1988; Press et al.,
1991) presence of bulky disease (Cabanillas et al., 1987),
number of sites of disease (Cabanillas et al., 1987) and
tumour burden (Velasquez et al., 1988). For HD the duration
of initial remission, presence of extranodal disease, LDH
level, haemoglobin and number of prior relapses influence the
outcome in patients treated with first line chemotherapy
(Hagemeister et al., 1987). In the IMVP-16 (ifosfamide,
methotrexate and VP-16) trial a response rate of 62% with
an impressive CR of 37% was obtained in 52 patients
(Cabanillas et al., 1982). However their groups of patients
had better prognostic factors that the patients in this study.
For example, the CR to prior chemotherapy was 40% vs
23% in our group and the duration of response to that
therapy was greater than 6 months in 60% of their patients,
but in only 14% of ours. The addition of methyl GAG (the
MIME protocol) did not improve the response but increased
the toxicity (Cabanillas et al., 1987). With the DHAP
regimen, a combination of dexamethasone, high dose Ara-C
and cisplatin, the MD Anderson group achieved an overall
response rate of 57.7% with a CR rate of 31% (Velasquez et
al., 1988). Unfortunately, toxicity was severe with a toxic
death rate of 17%. This group of 90 patients also had
slightly better prognostic features than our group; 48% had
achieved a CR with previous chemotherapy. It is of interest
that all CR but one were observed in patients with low
tumour burden. The results' obtained with the DHAP
regimen have been confirmed by others (Philip et al., 1991;
Press et al., 1991). Goss et al. with the DICE regimen
(dexamethasone, ifosfamide, cisplatin, etoposide) which is
similar to EPIC, achieved a CR in 27% of their patients, but
with greater toxicity (Goss et al., 1991).
While seven of nine (78%) patients with HD had a PR,
none achieved a CR. The analysis is confounded by the
subsequent use of high dose chemotherapy and ABMT in
three of the seven responding patients before a maximum
response was achieved. As previously stated, a third of the
patients had prior high dose chemotherapy and ABMT. In
one of them EPIC had to be stopped after one course due to
marrow failure, the other two attained a PR. Other investi-
gators have obtained CR in 13%-44% of patients relapsing
after MOPP and ABVD type combinations (Hagemeister et
al., 1987; Santoro et al., 1986; Pfeundschuh et al., 1987;
Tseng et al., 1987). Of particular interest are the results of
the Italian (Santoro et al., 1986) and German (Pfreundschuh
Table IV Salvage therapy in relapsed/refractory lymphoma
% Patients Median Median
No. of CR with Response Toxic Granulocyto- Granulocytopenia survival TTF (CR)
Regimen Ref. pats. prior Tx. (CR) deaths penic fever < 500pl-' (months) (months)
IMVP-16 Cabanillas 52 40 62 (37) 4 nm nm 15a 12b
(MD Anderson) 1982
MIME-NHL Cabanillas 208 42 60 (24) 6 59 nm 9 15c
(MD Anderson) 1987
IMVP-16/MIME Huijgens 18 33 50 (11) 6 nm 95 BMT BMT
(Amsterdam)
DHAP Velasquez 90 42 57.5 (31) 17 48 53d 6 15
(MD Anderson)
VIP (Indianapolis) Nichols 28 29 36 (8) 4 44 nm 7 nm
DICA (Ontario) Goss 22 41 77 (27) 9 41 41 nm nm
DHAP (Wash'ton) Press 39 nm 67 (23) 1 44 74 BMT BMT
EPIC (R.M.H.) 40 23 58 (28) 0 24 55c 9 18
nm = non mentioned aIntermed. gr NHL; bAll responders, measured from onset of response; cOnly responders; dGranulocytopenia <300PI1;
eWBC < 1000. BMT = Bone marrow transplant.LOW TOXICITY REGIMEN FOR RELAPSING LYMPHOMA 603
et al., 1987) groups, who achieved good CR (40 and 44%
respectively) with low toxicity in patients with poor prognos-
tic features. Published follow up is short, however. Results of
intensive therapy in these patients are promising (Vose et al.,
1990).
The EPIC regimen was associated with manageable tox-
icity in our group of heavily pretreated patients. There were
no toxic deaths and the low incidence of febrile episodes
associated with neutropenia in our group (8%) compares
favourably with the other regimens (Cabanillas et al., 1982,
Cabanillas et al., 1987; Velasquez et al., 1988; Hagemeister,
1987; Phillips et al., 1990; Press et al., 1991; Goss et al., 1991;
Huijgens et al., 1988; Nichols et al., 1988). Prophylactic
cotrimoxazole may have contributed to this low infection
rate and absence of mortality.
The poor outcome in the transformed group oflymphomas
has been previously found by some (Armitage et al., 1981)
but not by other authors (Acker et al., 1983).
Dose intensity is an accepted aim in the treatment of
aggressive lymphomas and has been related to relapse free
survival (De Vita et al., 1988). There is evidence suggesting a
steep dose-response relationship for cisplatin (Drewinko et
al., 1973; Ozols et al., 1984; Ozols et al., 1985; Levin &
Hryniuk, 1987). However a study in advanced germ cell
tumour proved that doubling the dose of cisplatin (from
20 mgm-2 for five consecutive days to 40mgm-2) did not
improve the outcome (Nichols et al., 1991). Cisplatin toxicity
on the other hand increases with higher doses (Drewinko et
al., 1973; Roelofs et al., 1984; Campbell et al., 1983; Kelsen
et al., 1985; Reddel et al., 1982) and with increasing
cumulative dose (Roelofs et al., 1984; Dominici et al., 1989).
The method of drug administration is also important
(Drewinko et al., 1973; Roelofs et al., 1984; Posner et al.,
1986). Doses up to 200 mg m-2 per course, either as a daily
bolus for 5 days or by continuous infusion have been given
with an important but acceptable increase in toxicity (Ozols
et al., 1985; Dominici et al., 1989; Ozols et al., 1988). We
have used an intermediate cisplatin dose (60 mg m-2 per
course). Other investigators have used 100 mg m-2 per
course, either as a continuous one day infusion (Velasquez et
al., 1988; Cabanillas et al., 1988; Philip et al., 1991; Press et
al., 1991) or a daily bolus for 4-5 days (Goss et al., 1991;
Nichols et al., 1988). The response rates and survival in these
trials are similar. It thus remains unproved that moderate
increase in cisplatin dose intensity results in a greater re-
sponse rate and survival in lymphoma.
Long term disease free survival in patients with resistant or
relapsed aggressive lymphomas treated with conventional
chemotherapy is extremely low. Efforts should probably be
directed towards improving the results of first line treatments
in patients with poor prognostic features. EPIC stands as a
second line chemotherapy regimen with a good overall re-
sponse rate and a low toxicity profile and could be a useful
combination for cytoreduction prior to high dose chemo-
therapy. The search for a satisfactory regimen for resistant
disease needs to be continued.
Dr Hickish is a CRC funded Senior Registrar and Dr Cunningham
was a CRC funded Senior Lecturer.
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